Grading Evidence-Based Guidelines-What Are the Issues?

American Journal of Kidney Diseases

Volumn 52, Issue 2, 2008, Pages 211-215

  Uhlig, Katrin ^a   Balk, Ethan M ^a   Lau, Joseph ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

CLINICAL PRACTICE; COMPARATIVE STUDY; DIALYSIS; EDITORIAL; EVIDENCE BASED MEDICINE; EXTERNAL VALIDITY; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH SERVICES RESEARCH; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; INTERNAL VALIDITY; KIDNEY TRANSPLANTATION; LOCAL ADAPTATION; NEPHROLOGY; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PROCESS DEVELOPMENT; QUALITY OF LIFE; SURVIVAL; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 47249126131     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.06.002     Document Type: Editorial

References (14)

1. Kidney Disease Improving Global Outcomes (KDIGO) website. http://www.kdigo.org Accessed June 23, 2008
2. Uhlig K., Balk E.M., Lau J., et al. Clinical practice guidelines in nephrology-for worse or for better. Nephrol Dial Transplant 21 (2006) 1145-1153
3. Atkins D., Best D., Briss P.A., et al. Grading quality of evidence and strength of recommendations. BMJ 328 (2004) 1490
4. Uhlig K., Macleod A., Craig J., et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70 (2006) 2058-2065
5. Sawaya G.F., Guirguis-Blake J., LeFevre M., et al. Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med 147 (2007) 871-875
6. Wolff T., Guirguis-Blake J., Miller T., et al. Screening for carotid artery stenosis: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 147 (2007) 860-870
7. KDIGO. KDIGO Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl 109 (2008) S1-S99
8. Gordon C., Uhlig K., Lau J., et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection-a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 51 (2008) 263-277
9. Pagliari C., Grimshaw J., and Eccles M. The potential influence of small group processes on guideline development. J Eval Clin Pract 7 (2001) 165-173
10. Djulbegovic B., Frohlich A., and Bennett C.L. Acting on imperfect evidence: How much regret are we ready to accept?. J Clin Oncol 23 (2005) 6822-6825
11. West S., King V., Carey T., et al. Systems to Rate the Strength of Scientific Evidence. Evidence Report/Technology Assessment No. 47. AHRQ Publication No 02-E016 (2002), Agency for Healthcare Research and Quality, Rockville, MD April
12. Schunemann H.J., Best D., Vist G., et al. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ 169 (2003) 677-680
13. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117 (2008) 261-295
14. Glasziou P., Vandenbroucke J.P., and Chalmers I. Assessing the quality of research. BMJ 328 (2004) 39-41